We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Commercial System Effective for Cefiderocol Susceptibility Testing

By LabMedica International staff writers
Posted on 11 Jul 2019
Print article
Image: The Sensititre Complete Automated Antibiotic Susceptibility Testing (AST) System performs all susceptibility testing on a single platform utilizing the superior sensitivity of true MIC results (Photo courtesy of Thermo Fisher Scientific).
Image: The Sensititre Complete Automated Antibiotic Susceptibility Testing (AST) System performs all susceptibility testing on a single platform utilizing the superior sensitivity of true MIC results (Photo courtesy of Thermo Fisher Scientific).
The novel formulation of the cephalosporin antibiotic makes it very effective against gram-negative non-fastidious bacteria that are otherwise highly resistant to antibiotics, including carbapenem-resistant strains of Enterobacteriaceae and non-fermenters.

In microbiology, the minimum inhibitory concentration (MIC) is the lowest concentration of a chemical, usually a drug, which prevents visible growth of bacterium. MIC depends on the microorganism, the affected human being (in vivo only), and the antibiotic itself.

An international team of scientists working with Thermo Fisher Scientific (Cleveland, Ohio, USA) conducted a study that involved 374 recent clinical isolates, which included Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia marcescens, Pseudomonas aeruginosa, and Acinetobacter baumannii. One of the four study sites additionally used 147 Centers for Disease Control and Prevention challenge isolates. Three sites also used 11 reproducibility isolates, with three of these isolates being tested each day for three days. Finally, all four sites tested two quality control strains: E. coli ATCC 25922 and P. aeruginosa ATCC 27853.

The team tested a commercially prepared dried minimum inhibitory concentration (MIC) susceptibility system, the Thermo Fisher Scientific Sensititre, and demonstrated an equivalent level of performance compared with the Clinical & Laboratory Standards Institute (CLSI) M07/M100 and the International Organization for Standardization (ISO) 20776-1 reference broth microdilution (BMD) method when testing cefiderocol against Gram-negative non-fastidious organisms.

Overall agreement for the reproducibility (± 1 log2 dilution) concerning the most frequent (or modal) MIC value using automated and manual reading was 95.0% and 95.3%, respectively. The lowest agreement between the two test methods was 90.0% for Enterobacter spp., followed by 92.0% for Citrobacter spp. The strongest agreement was for P. aeruginosa (97.5%). The agreement among the four testing sites was high, at about 95%.

Thomas C. Lewis, BSc, a Research and Development Project Leader at Thermo Fisher Scientific, said, “The high level of agreement obtained by the Sensititre susceptibility system and the CLSI/ISO BMD method suggests that this is an acceptable method for susceptibility testing of cefiderocol. The results are available within 18 to 24 hours, versus several days for the broth. Plus, the testing materials can be kept on the laboratory shelf at room temperature before being used, which is a lot more convenient.” The study was presented at the Annual meeting of the American Society of Microbiology, held June 7-11, 2019, in Atlanta, GA, USA.

Related Links:
Thermo Fisher Scientific

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics